US2017114321A1PendingUtilityA1
Methods for eliminating at least a substantial portion of a clonal antigen-specific memory t cell subpopulation
Est. expiryJun 28, 2022(expired)· nominal 20-yr term from priority
A61P 37/00C12N 2502/1114C12N 5/0087C12N 2501/48A61K 35/17C12N 5/0636A61K 40/416A61K 40/46A61K 40/42A61K 40/32A61K 40/22A61K 40/11Y02A50/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.
Claims
exact text as granted — not AI-modified1 - 73 . (canceled)
74 . A method for eliminating at least a substantial portion of a clonal T cell subpopulation from a mixed population of T cells from an individual, comprising,
exposing a population of cells, wherein at least a portion thereof comprises T cells, to one or more pro-apoptotic or growth inhibiting compositions, wherein the exposure induces apoptosis or growth inhibition in at least a substantial portion of at least one clonal T cell population present in the mixed population of T cells, thereby eliminating at least a substantial portion of the clonal T cell population from the mixed population of T cells.
75 . The method of claim 74 , further comprising expanding the remaining mixed population of T cells.
76 . The method of claim 75 , wherein the remaining mixed population of cells is expanded by exposing the remaining mixed population of cells to a surface wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the remaining T cells and stimulates the remaining T cells.
77 . A population of T cells generated according to the method of claim 74 .
78 . The method of claim 74 , wherein the pro-apoptotic composition comprises allogeneic or xenogeneic cells.
79 . A method for treating autoimmune disease in a patient comprising administering to the patient the population of T cells of claim 77 .
80 . The method of claim 76 , wherein one agent is an antibody or a fragment thereof, and another agent is an antibody or a fragment thereof.
81 . The method of claim 76 , wherein one agent is an anti-CD3 antibody and another agent is an anti-CD28 antibody.
82 . A method for eliminating at least a substantial portion of a clonal T cell subpopulation from a mixed population of T cells from an individual, comprising,
(a) exposing a population of cells wherein at least a portion thereof comprises T cells to one or more compositions that sensitize at least a portion of the T cells to further activation or stimulation, and (b) exposing the population of cells to a surface wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the sensitized T cells and stimulates the sensitized T cells, wherein the exposure of the sensitized T cells to the surface is for a time sufficient to induce apoptosis of the sensitized T cells; thereby eliminating the sensitized T cells from the population.
83 . The method of claim 82 , wherein step (b) further comprises exposing the population of cells to the surface for a time sufficient to stimulate at least a portion of the remaining T cells and wherein the at least a portion of the remaining cells proliferates.
84 . The method of claim 82 , wherein the surface has attached thereto a first agent that ligates a first T cell surface moiety of a T cell; and the same or a second surface has attached thereto a second agent that ligates a second moiety of the T cell, wherein the ligation by the first and second agent induces proliferation of the T cell.
85 . A population of T cells generated according to the method of claim 82 .
86 . The method of claim 82 , wherein the exposure of the cells to the surface is for a time sufficient to increase polyclonality.
87 . A method for generating a substantially pure population of CD3+/CD28+ T cells from a population of T cells, comprising:
exposing a population of cells, wherein at least a portion thereof comprises T cells, ex vivo to a composition that stimulates and/or selects surface CD3 and CD28 molecules; thereby generating a substantially pure population of CD3+/CD28+ T cells.
88 . A composition comprising an in vitro, mixed population of T cells comprising polyclonal T cells and antigen-specific T cells,
wherein the polyclonal T cells are capable of expanding and the antigen-specific T cells are not capable of expanding.
89 . The composition of claim 88 , further comprising a surface having attached thereto agents with binding activity to cell surface moieties on the surfaces of T cells in the mixed population,
wherein the agents having binding affinity for CD3 protein complexes and CD28 proteins, and.
90 . The composition of claim 89 , wherein the ratio of surface to cells is at least 5:1
91 . The composition of claim 89 , wherein one of the agents is an anti-CD3 antibody or an anti-CD3 antibody fragment.
92 . The composition of claim 89 , wherein one of the agents is an anti-CD28 antibody or an anti-CD28 antibody fragment.Join the waitlist — get patent alerts
Track US2017114321A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.